| Literature DB >> 32482664 |
Caitlin M O'Connor1, Goutham Narla2.
Abstract
Although mutations in SF3B1 are the most common RNA-splicing factor mutations in cancer, determining the downstream missplicing events that drive tumorigenesis has remained challenging. Liu and colleagues present a model by which mutant SF3B1 tumors displayed high levels of oncogenic MYC activity through the missplicing of PP2A-B56α, a key post-translational regulator of MYC stability, providing a new therapeutic target and driver of SF3B1-mediated tumorigenesis.See related article by Liu et al., p. 806. ©2020 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32482664 PMCID: PMC8162994 DOI: 10.1158/2159-8290.CD-20-0358
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 38.272